Polpharma Biologics Announces FDA Approval of Tyruko® -

Polpharma Biologics Announces FDA Approval of Tyruko® -  First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple SclerosisAMSTERDAM, The Netherlands, August 25, 2023 / B3C newswire / -- Polpharma Biologics, an international biotech company dedicated to the development and ma...

Related Keywords

Netherlands , Amsterdam , Noord Holland , Michael Soldan , Polpharma Biologics , European Medicines Agency , Polpharma Biologics Group , Drug Administration , Polpharma Biologics Announces , First And Only Approved Biosimilar , Relapsing Forms , Chief Executive Officer , Risk Evaluation , Mitigation Strategy ,